ARXS
Arxis, Inc. Class A Common StockNASDAQINDUSTRIALSAEROSPACE & DEFENSE
Key Statistics
Market Cap
$14.28B
P/E Ratio
—
EPS
$-0.12
Beta
—
52W High
$39.45
52W Low
$33.15
50-Day MA
$35.75
200-Day MA
$35.75
Dividend Yield
—
Profit Margin
2.89%
Forward P/E
53.76
PEG Ratio
—
About Arxis, Inc. Class A Common Stock
Arxis, Inc. (ARXS) is an innovative biotechnology company focused on developing cutting-edge therapies aimed at treating complex diseases. With a strong emphasis on research and development, Arxis leverages advanced scientific techniques to advance its proprietary drug pipeline, targeting both rare and prevalent conditions. The company is committed to improving patient outcomes through its robust clinical programs and collaborative partnerships within the healthcare ecosystem. As Arxis continues to progress its clinical trials, it positions itself as a dynamic player in the biotechnology sector, poised for potential growth and value creation for investors.
Fundamentals
| Revenue (TTM) | $1.59B |
| Gross Profit (TTM) | $772.92M |
| EBITDA | $498.16M |
| Operating Margin | 18.70% |
| Return on Equity | 1.51% |
| Return on Assets | 2.89% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | 3.41 |
| Price-to-Sales (TTM) | 8.98 |
| EV/Revenue | 9.82 |
| EV/EBITDA | 50.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $69.73M |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.59% |
More INDUSTRIALS Stocks
Data last updated: 5/25/2026